Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-11-14

Clinical Trial Update: Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial [Phase 1]

View source ↗

Summary

Phase 1 trial update showing completion of the RIPT study evaluating Ranibizumab for idiopathic parafoveal telangiectasia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lucentis (ranibizumab)

Snippet

Sponsor: Johns Hopkins University | Conditions: Telangiectasia | Phase 1 | Status: COMPLETED